January 2020 Newsletter »
July 2019 Newsletter »

January 2019 Newsletter »




March 24, 2020: 

AACE Position Statement: Coronavirus (COVID-19) and People with Adrenal Insufficiency and Cushing’s Syndrome


March 9, 2020: 

FDA draft guidance eliminates CV outcomes trial recommendation for diabetes drug approvals

February 15, 2020: 

FDA recall on Medtronic pumps - 600 series

February 13, 2020:

FDA voluntary recall of anti-obesity drug Belviq

January 28, 2020:

FDA okays triple-combo pill for type 2 diabetes

January 21, 2020: 

FDA approves first treatment for thyroid eye disease


January 16, 2020:

FDA Approves Semaglutide Injection for Cardiovascular Risk Reduction

January 6, 2020:

Fiasp is now approved for children with diabetes


December 13, 2019:

FDA approves Tandem Diabetes Care Control IQ Technology, a integrated insulin pump + continuous glucose sensor


October 22, 2019: 
FDA OKs Faster-Acting Insulin Aspart for Pump Use (Fiasp)


October 21, 2019: 
FDA OKs Dapagliflozin to Reduce HF Hospitalization in Diabetes (Farxiga)


September 30, 2019: 
FDA OKs Canagliflozin to Curtail Diabetic Kidney Disease (Invokana)



CMHC’s Monthly Newsletter:



ASEPA members meet twice a year at the following conferences: AAPA and AACE. We also meet informally at the MEDS East and MEDS West conferences.


Throughout the year, board members communicate frequently via email and conference calls. 


We welcome your feedback! For more information, questions, suggestions for the website, or if you are interested in precepting students, contact us at 


You may also reach out to us below:


281 E Colorado Blvd
PO Box 1145
Pasadena, CA 91102